GlassScriptPhysician profile
Geetha Kamath
NPI 1669435004
$16,707.13
in general payments reported to CMS, 2019-2025
77 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $1,525 · 2021: $108 · 2022: $2,426 · 2023: $3,537 · 2024: $3,721 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,255 · Long Term Medical Supply Or Device Loan: $1,482 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,255.39 |
| Long Term Medical Supply Or Device Loan | $1,482.09 |
| Education | $291.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,159.59 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $935.65 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $919.10 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $850.65 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $764.75 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $471.65 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Celgene Corporation | $446.49 | 2019-2025 | Reblozyl, Opdualag |
| Seagen INC. | $416.12 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Astrazeneca Pharmaceuticals LP | $401.98 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Incyte Corporation | $399.58 | 2019-2025 | Jakafi, Monjuvi |
| Lilly USA, LLC | $384.06 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $377.75 | 2019-2025 | |
| Pfizer INC. | $366.14 | 2019-2025 | |
| Gilead Sciences, INC. | $356.10 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $337.77 | 2019-2025 | Venclexta, Tecentriq, Phesgo |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Kamath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.